Executive record

Amy Burroughs

Public governance roles and source-backed Claims for this individual.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:amy-burroughsVersion: public-0As of: 2026-09-29

Not yet claimed5 published Claims1 sources

Key Claims

Biography

Amy Burroughs has served as Chief Executive Officer and Director since February 2024. Her detailed biographical information is referenced under the board of directors section of the filing.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Executive career

  1. 2025 to end not publishedExecutive title: Chief Executive Officer and Director · Organization not publishedTERN DEF 14A executive officers

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

1 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. TERN DEF 14A executive officers

    sec filing · Source published: Apr 29, 2025 · Retrieved: May 10, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 10, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 10, 2026
    • Executive company: Executive at Terns Pharmaceuticals · Claim reviewed: May 10, 2026
    • Executive title: Executive title: Chief Executive Officer and Director · Claim reviewed: May 10, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 10, 2026